Clinical Trial Update: Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of anlotinib with PD-L1 inhibitor TQB2450 in advanced esophageal squamous cell carcinoma is ongoing, with status curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN